Lung Cancer Screening in 2026: Who Should Get a Low-Dose CT and How It Prevents Advanced Disease

Why Lung Cancer Screening Matters

Lung cancer remains the leading cause of cancer death in the United States, according to the Centers for Disease Control and Prevention (CDC). Most deaths occur because the disease is found at a late stage, when treatment is less likely to cure it.

Screening aims to find lung cancer earlier—before symptoms appear—when it may be easier to treat. For people at high risk, annual screening with a low-dose CT (LDCT) scan has been shown to reduce the risk of dying from lung cancer. It does not prevent cancer from developing, and it does not guarantee early detection, but it can lower the chance of dying from the disease in certain groups.

As of 2026, national recommendations for who should be screened are based on strong evidence from large randomized clinical trials and are summarized by the U.S. Preventive Services Task Force (USPSTF).

Who Qualifies in 2026: Breaking Down the USPSTF Criteria

The USPSTF gives annual lung cancer screening with low-dose CT a Grade B recommendation for adults who meet all of the following criteria:

Age 50 to 80 years
A 20 pack-year or greater smoking history
Currently smoke or have quit within the past 15 years

A pack-year is a way to measure lifetime smoking exposure. One pack-year equals smoking one pack (20 cigarettes) per day for one year. For example:

1 pack a day for 20 years = 20 pack-years
2 packs a day for 10 years = 20 pack-years
Half a pack a day for 40 years = 20 pack-years

Screening is not recommended for people who never smoked or who have a lower smoking history, because the balance of benefits and harms is less favorable in lower-risk groups.

According to the USPSTF, screening should stop if a person:

Has not smoked for 15 years, or
Develops a health problem that substantially limits life expectancy, or
Is unwilling or unable to undergo lung surgery if cancer is found.

What Is a Low-Dose CT Scan?

A low-dose CT scan is a specialized X-ray that takes detailed images of the lungs. It uses much less radiation than a standard diagnostic CT scan.

The test itself is quick and painless. You lie on a table that slides into a scanner. There are no needles, no contrast dye in most cases, and no sedation. The scan usually takes only a few minutes.

If the scan shows a small lung nodule (a spot in the lung), that does not automatically mean cancer. In fact, most nodules found on screening are not cancer. Follow-up may include repeat imaging months later to see if the nodule changes, or in some cases, additional tests.

What the Evidence Shows: Mortality Reduction From Randomized Trials

The recommendation for screening is based on large randomized controlled trials—the strongest type of study for testing whether an intervention saves lives.

The National Cancer Institute’s National Lung Screening Trial (NLST) enrolled more than 53,000 high-risk adults and compared low-dose CT with chest X-ray. It found that LDCT screening reduced lung cancer deaths by about 20% in the screened group.

Another large European trial, known as NELSON, also found a reduction in lung cancer mortality among high-risk participants screened with low-dose CT.

Evidence reviews published alongside the USPSTF recommendation in JAMA concluded that annual LDCT screening reduces lung cancer mortality in high-risk adults. However, the benefit applies specifically to people who meet the eligibility criteria—not to the general population.

It is also important to understand that screening lowers the risk of dying from lung cancer; it does not eliminate the risk.

Possible Harms and Trade-Offs

Screening comes with downsides, and understanding them is part of informed decision-making.

False Positives

Many people who are screened will have an abnormal finding that turns out not to be cancer. These false positives can lead to repeat scans, anxiety, and sometimes invasive procedures such as biopsies.

Overdiagnosis

Some cancers found on screening may grow so slowly that they would not have caused symptoms during a person’s lifetime. Detecting and treating these cancers is called overdiagnosis. It is difficult to measure precisely but is a recognized risk.

Radiation Exposure

Low-dose CT uses less radiation than a standard CT scan, but repeated annual scans add up over time. For eligible high-risk adults, experts judge that the mortality benefit outweighs this radiation risk, but it is not zero.

Incidental Findings

CT scans sometimes reveal unrelated findings outside the lungs. These can lead to additional testing, which may or may not be necessary.

Shared Decision-Making: A Required Conversation

The USPSTF and Medicare both emphasize shared decision-making before starting screening. This means you and your clinician should discuss:

Your personal risk based on smoking history and health status
The potential benefits of early detection
The possible harms, including false positives and follow-up tests
Your willingness to undergo treatment if cancer is found

For people who currently smoke, counseling and support for quitting are a critical part of this conversation.

Insurance and Medicare Coverage

Under the Affordable Care Act, most private insurance plans must cover USPSTF Grade B preventive services without cost-sharing when provided by an in-network clinician. That includes annual low-dose CT screening for eligible adults.

Medicare also covers lung cancer screening for qualifying beneficiaries, with specific eligibility criteria that closely follow national recommendations. Medicare requires a counseling and shared decision-making visit before the first screening.

Coverage details can vary, so it is reasonable to confirm eligibility and any potential out-of-pocket costs with your insurer or healthcare provider before scheduling the scan.

Screening and Smoking Cessation: How They Work Together

Screening does not replace quitting smoking. According to the CDC, stopping smoking remains the most effective way to reduce the risk of lung cancer, heart disease, stroke, and chronic lung disease.

Even among people who qualify for screening, quitting smoking further lowers future risk. Screening is best understood as an added layer of protection for people at high risk—not as a substitute for prevention.

Free resources, including quit lines and counseling, are available nationwide through CDC-supported programs.

Questions to Ask Your Doctor

Do I meet the 20 pack-year threshold?
How might my other health conditions affect the benefits or risks of screening?
What happens if my scan finds a nodule?
When would screening stop in my case?
What support is available to help me quit smoking?

What This Means for Readers

If you are between 50 and 80 and have smoked the equivalent of 20 pack-years or more—and you currently smoke or quit within the past 15 years—you may qualify for annual low-dose CT screening.

For people at high risk, screening reduces the chance of dying from lung cancer. But it also brings trade-offs, including false positives and follow-up testing.

In the bigger picture of chronic disease prevention, lung cancer screening is one tool. Quitting smoking, avoiding secondhand smoke, and addressing other health risks remain central to protecting long-term health.

If you think you might qualify, a conversation with your healthcare provider is the right next step.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.